1
Clinical Trials associated with C213 (Zosano Pharma)Randomized, Double-Blind, Multi-Center, Parallel-Group Comparison of the Efficacy and Safety of the C213 (Zolmitriptan Microneedle System) to Placebo for the Acute Treatment of Cluster Headaches
This is a double-blind, placebo-controlled study. Subjects who meet the entry criteria will be randomized o receive one of three blinded treatments [C213 1.9 mg patch and placebo patch; C213 3.8 mg (1.9 mg x 2 patches), two placebo patches] on Day 1 and will have up to 48 weeks to confirm and treat a cluster headache. Subjects will self-administer the patches and respond to questions in the electronic diary (eDiary) until 1-hour post treatment administration.
100 Clinical Results associated with C213 (Zosano Pharma)
100 Translational Medicine associated with C213 (Zosano Pharma)
100 Patents (Medical) associated with C213 (Zosano Pharma)
100 Deals associated with C213 (Zosano Pharma)